ArticlePediatric radiology2026
The effect of T2 signal heterogeneity on gadolinium enhancement in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease: a quantitative magnetic resonance imaging study.
Article in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT2-hyperintensity and gadolinium enhancement mark inflammation in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), yet the significance of T2 signal heterogeneity remains underexplored.
objectiveTo investigate the relationship between quantitative T2 signal heterogeneity metrics and lesion enhancement. MATERIALS AND
methodsWe retrospectively reviewed 70 MOGAD pediatric patients with 190 brain lesions (99 enhanced, 91 non-enhanced). Twenty-six patients underwent follow-up magnetic resonance imaging (MRI) (median 39 days) evaluating 57 baseline-enhanced lesions. Quantitative analysis included lesion area, T2 signal intensity (mean, standard deviation [SD], maximum [Max], minimum [Min]), and normalized ratios to the corpus callosum (CC).
resultsAcute enhanced lesions exhibited larger axial areas and elevated T2 heterogeneity ratios (Max/CC, SD/CC, Max-Min/CC and Max/Min, all P<0.001) and Mean/CC (P=0.001) versus non-enhanced lesions. Follow-up lesions showed smaller areas (P<0.001) and normalized T2 ratios (Max/CC, SD/CC, Max-Min/CC and Max/Min, all P<0.001) versus their acute-phase counterparts. Analysis of covariance (ANCOVA) identified significant group×lesion area interaction effects for Max/CC, Max-Min/CC, and Max/Min (all P<0.05). Acute non-enhancing lesions and follow-up lesions showed no significant differences across all quantitative parameters (all P>0.05). The Max/Min ratio demonstrated superior diagnostic performance for lesion-level enhancement prediction (area under the receiver operating characteristic curve [AUC] 0.802, 95% confidence interval [CI] 0.739-0.864) and patient-level classification (AUC 0.837, 95% CI 0.739-0.934).
conclusionT2 signal heterogeneity can suggest inflammatory activity in MOGAD. The Max/Min ratio provides a clinically applicable predictor for lesion enhancement and disease monitoring.
Indexed as
Identifiers
42295378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.